March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.
The FDA approved Qfitlia (fitusiran) for hemophilia A or B prophylaxis in patients aged 12 and older, offering reduced bleeding rates with bi-monthly dosing.
FDA approves Vykat XR as first treatment for hyperphagia in patients with Prader-Willi syndrome; decision follows extended review and long-term efficacy data.
A new study identifies glycerol intoxication syndrome in children after consuming slush ice drinks, leading to hypoglycemia, metabolic acidosis, and altered consciousness.